MX9305294A - Compuestos de decahidroisoquinolina, procedimiento para su preparacion y formulacion farmaceutica que los comprende. - Google Patents
Compuestos de decahidroisoquinolina, procedimiento para su preparacion y formulacion farmaceutica que los comprende.Info
- Publication number
- MX9305294A MX9305294A MX9305294A MX9305294A MX9305294A MX 9305294 A MX9305294 A MX 9305294A MX 9305294 A MX9305294 A MX 9305294A MX 9305294 A MX9305294 A MX 9305294A MX 9305294 A MX9305294 A MX 9305294A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- decahydroisokinoline
- procedure
- preparation
- pharmaceutical formulation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical class C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 abstract 1
- 229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Esta invención proporciona nuevos compuestos de decahidroisoquinolina, que son útiles como antagonistas del receptor de amino ácidos excitadores y en el tratamiento de transtornos neurológicos. Esta invención proporciona también procedimientos sintéticos para preparar decahidroisoquinolinas así como nuevos intermedios en su síntesis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/939,780 US5284957A (en) | 1992-09-03 | 1992-09-03 | Excitatory amino acid receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9305294A true MX9305294A (es) | 1994-06-30 |
Family
ID=25473721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9305294A MX9305294A (es) | 1992-09-03 | 1993-08-31 | Compuestos de decahidroisoquinolina, procedimiento para su preparacion y formulacion farmaceutica que los comprende. |
Country Status (27)
Country | Link |
---|---|
US (7) | US5284957A (es) |
EP (1) | EP0590789B9 (es) |
JP (1) | JP3601840B2 (es) |
KR (1) | KR100274367B1 (es) |
CN (1) | CN1043762C (es) |
AT (1) | ATE234287T1 (es) |
AU (1) | AU656482B2 (es) |
BR (1) | BR9303495A (es) |
CA (2) | CA2484248A1 (es) |
CZ (1) | CZ285049B6 (es) |
DE (1) | DE69332754T2 (es) |
DK (1) | DK0590789T3 (es) |
ES (1) | ES2194844T3 (es) |
FI (1) | FI933810A (es) |
HK (1) | HK1013989A1 (es) |
HU (2) | HU224015B1 (es) |
IL (1) | IL106809A (es) |
MX (1) | MX9305294A (es) |
MY (1) | MY131442A (es) |
NO (1) | NO304072B1 (es) |
NZ (1) | NZ248513A (es) |
PH (1) | PH31250A (es) |
PL (1) | PL173809B1 (es) |
PT (1) | PT590789E (es) |
RU (1) | RU2117661C1 (es) |
SG (1) | SG45319A1 (es) |
ZA (1) | ZA936231B (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2087812B1 (es) * | 1993-07-02 | 1997-03-16 | Lilly Co Eli | Derivados de decahidroisoquinolina utiles como antagonistas de los receptrores de los aminoacidos excitadores. |
US5580877A (en) * | 1994-04-25 | 1996-12-03 | Merck Sharp & Dohme Ltd. | Pyrazolo-quinoline derivatives for treating cerebral ischemia |
US5446051A (en) * | 1994-05-31 | 1995-08-29 | Eli Lilly And Company | Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists |
US5723414A (en) * | 1996-01-24 | 1998-03-03 | Rohm And Haas Company | 5-aryl-isoxazolinones and herbicidal use thereof |
PT807633E (pt) * | 1996-05-15 | 2003-02-28 | Pfizer | Novas pirimidin-4-onas substituidas em 2,3, e fundidas com heteroarilo em (5,6) |
SK284108B6 (sk) | 1996-05-15 | 2004-09-08 | Pfizer Inc. | 2,3-Disubstituované 4(3H)-chinazolinóny, ich použitie a farmaceutické kompozície s ich obsahom |
WO1998045270A1 (en) | 1997-04-07 | 1998-10-15 | Eli Lilly And Company | Pharmacological agents |
US6627755B1 (en) | 1997-06-09 | 2003-09-30 | Pfizer Inc | Quinazolin-4-one AMPA antagonists |
IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
US6323208B1 (en) | 1997-09-05 | 2001-11-27 | Pfizer Inc | Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones |
EP1066039A4 (en) | 1998-03-02 | 2003-02-26 | Cocensys Inc | SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES |
DE60032905T2 (de) | 1999-07-06 | 2007-10-18 | Eli Lilly And Co., Indianapolis | Selektive iglur5 rezeptorantagonisten zur behandlung der migräne |
ATE240299T1 (de) * | 1999-07-06 | 2003-05-15 | Lilly Co Eli | Diester prodrugs von decahydroischinoline-3- carbonsäure |
US6313159B1 (en) | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
AU2574801A (en) | 1999-12-22 | 2001-07-03 | Eli Lilly And Company | Selective iGLUR5 receptor antagonists |
AU2002227020A1 (en) * | 2001-01-05 | 2002-07-16 | Eli Lilly And Company | Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists |
US6924294B2 (en) | 2001-01-05 | 2005-08-02 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
US7205313B2 (en) * | 2001-01-05 | 2007-04-17 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
EP1351955A1 (en) * | 2001-01-05 | 2003-10-15 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
PT1368032E (pt) * | 2001-01-05 | 2008-09-04 | Lilly Co Eli | Antagonistas de receptores dos aminoácidos excitadores |
AU2002228736A1 (en) * | 2001-01-05 | 2002-07-16 | Eli Lilly And Company | Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists |
GB0106858D0 (en) * | 2001-03-20 | 2001-05-09 | Perkins Engines Co Ltd | An accessory drive for driving an engine accessory |
GB0128996D0 (en) * | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
US7091249B2 (en) * | 2001-12-26 | 2006-08-15 | University Of Iowa Research Foundation | Drugs for spinal anesthesia |
AU2003219955A1 (en) * | 2002-03-22 | 2003-10-13 | Eli Lilly And Company | Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists |
US20050176068A1 (en) * | 2002-04-26 | 2005-08-11 | Emmert-Buck Michael R. | Direct cell target analysis |
KR100757787B1 (ko) * | 2002-04-26 | 2007-09-11 | 일라이 릴리 앤드 캄파니 | 진통제로서의 데카히드로이소퀴놀린-3-카르복실산의 에스테르 유도체 |
GB0222056D0 (en) * | 2002-09-23 | 2002-10-30 | Novartis Ag | Process for the manufacture of organic compounds |
US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
US20060220794A1 (en) * | 2005-04-04 | 2006-10-05 | Jeffrey Zhu | Phase modulation for backscatter transponders |
WO2007101116A2 (en) * | 2006-02-24 | 2007-09-07 | The Trustees Of Columbia University In The City Of New York | Glur2 receptor modulators |
US20080108622A1 (en) * | 2006-10-19 | 2008-05-08 | Eisenach James C | Combination therapy for the treatment of pain |
US20080108603A1 (en) * | 2006-10-19 | 2008-05-08 | Eisenach James C | Combination therapy for the treatment of pain |
US20090270508A1 (en) * | 2007-02-23 | 2009-10-29 | James Eric Gouaux | GluR2 receptor modulators |
EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
CN101812031A (zh) * | 2010-04-29 | 2010-08-25 | 南通市华峰化工有限责任公司 | 一种5-羟烷基四氮唑的高压生产方法 |
US9505728B2 (en) | 2012-03-09 | 2016-11-29 | Inception 2, Inc. | Triazolone compounds and uses thereof |
CN104918922B (zh) | 2012-12-20 | 2017-04-26 | 因森普深2公司 | ***酮化合物及其用途 |
TWI593692B (zh) * | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
CN105579440A (zh) | 2013-09-06 | 2016-05-11 | 因森普深2公司 | ***酮化合物及其应用 |
CA3066711A1 (en) | 2017-07-31 | 2019-02-07 | Novartis Ag | Use of mavoglurant in the reduction of ***e use or in preventing relapse into ***e use |
MX2022016223A (es) * | 2020-07-02 | 2023-02-23 | Sea Pharmaceuticals Llc | Composiciones farmaceuticas de acido 6-(2-(2h-tetrazol-5-il)etil)- 6-fluorodecahidroisoquinolina-3-carboxilico y derivados de ester del mismo. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK704488D0 (da) * | 1988-12-19 | 1988-12-19 | Novo Industri As | Nye n-substituerede azaheterocykliske carboxylsyrer |
US4897490A (en) * | 1987-02-25 | 1990-01-30 | Bristol-Meyers Company | Antihypercholesterolemic tetrazole compounds |
US4824959A (en) * | 1988-02-18 | 1989-04-25 | Bristol-Myers Company | Intermediates for antihypercholesterolemic tetrazole compounds |
US4902695A (en) * | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
US5192751A (en) * | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
-
1992
- 1992-09-03 US US07/939,780 patent/US5284957A/en not_active Expired - Lifetime
-
1993
- 1993-08-25 ES ES93306745T patent/ES2194844T3/es not_active Expired - Lifetime
- 1993-08-25 ZA ZA936231A patent/ZA936231B/xx unknown
- 1993-08-25 SG SG1996003438A patent/SG45319A1/en unknown
- 1993-08-25 DK DK93306745T patent/DK0590789T3/da active
- 1993-08-25 AT AT93306745T patent/ATE234287T1/de active
- 1993-08-25 DE DE69332754T patent/DE69332754T2/de not_active Expired - Lifetime
- 1993-08-25 CZ CZ931745A patent/CZ285049B6/cs not_active IP Right Cessation
- 1993-08-25 EP EP93306745A patent/EP0590789B9/en not_active Expired - Lifetime
- 1993-08-25 US US08/111,747 patent/US5399696A/en not_active Expired - Lifetime
- 1993-08-25 PT PT93306745T patent/PT590789E/pt unknown
- 1993-08-26 BR BR9303495A patent/BR9303495A/pt not_active Application Discontinuation
- 1993-08-26 CA CA002484248A patent/CA2484248A1/en not_active Abandoned
- 1993-08-26 IL IL10680993A patent/IL106809A/en not_active IP Right Cessation
- 1993-08-26 CA CA002104909A patent/CA2104909C/en not_active Expired - Lifetime
- 1993-08-27 NZ NZ248513A patent/NZ248513A/en unknown
- 1993-08-27 PH PH46762A patent/PH31250A/en unknown
- 1993-08-30 HU HU9302453A patent/HU224015B1/hu active IP Right Grant
- 1993-08-31 FI FI933810A patent/FI933810A/fi unknown
- 1993-08-31 AU AU46003/93A patent/AU656482B2/en not_active Expired
- 1993-08-31 RU RU93049265A patent/RU2117661C1/ru active
- 1993-08-31 NO NO933100A patent/NO304072B1/no not_active IP Right Cessation
- 1993-08-31 MX MX9305294A patent/MX9305294A/es unknown
- 1993-09-01 KR KR1019930017398A patent/KR100274367B1/ko not_active IP Right Cessation
- 1993-09-01 MY MYPI93001753A patent/MY131442A/en unknown
- 1993-09-01 JP JP21744193A patent/JP3601840B2/ja not_active Expired - Lifetime
- 1993-09-01 CN CN93117627A patent/CN1043762C/zh not_active Expired - Lifetime
- 1993-09-01 PL PL93300250A patent/PL173809B1/pl unknown
-
1994
- 1994-11-21 US US08/343,079 patent/US5637712A/en not_active Expired - Lifetime
-
1995
- 1995-06-01 US US08/457,766 patent/US5675008A/en not_active Expired - Lifetime
- 1995-06-01 US US08/456,439 patent/US5670516A/en not_active Expired - Lifetime
- 1995-06-01 US US08/457,556 patent/US5606062A/en not_active Expired - Lifetime
- 1995-06-01 US US08/456,577 patent/US5648492A/en not_active Expired - Lifetime
- 1995-06-22 HU HU95P/P00401P patent/HU211992A9/hu unknown
-
1998
- 1998-12-23 HK HK98115176A patent/HK1013989A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9305294A (es) | Compuestos de decahidroisoquinolina, procedimiento para su preparacion y formulacion farmaceutica que los comprende. | |
MX19448A (es) | Procedimiento para la prreparacion de compuestos antagonistas de los receptores de aminoacidos excitadores; compuestos obtenidos y composicion farmaceutica que los incluye. | |
AR002289A1 (es) | Derivados de acetamida, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y las aplicaciones de dichos compuestos comoansioliticos y en el tratamiento de enfermedades inmuno-inflamatorias. | |
AR006119A1 (es) | Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos | |
DK1196397T3 (da) | Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet | |
ES2191187T3 (es) | Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa. | |
MX9302888A (es) | 1,2,3,4-tetrahidroisoquinolinas substituidas con propiedades antagonistas del receptor de angiotensina ii. | |
NO944578L (no) | Eksitatoriske aminosyre reseptor antagonister | |
GT199700095A (es) | Derivados 6,5-heterobiciclicos sustituidos. | |
AR002705A1 (es) | Un nuevo compuesto de indolina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen. | |
IS6922A (is) | Heterófjölhringjaefnasambönd og notkun þeirra semmetabótrópísk mótlyf gegn glútamat viðtökum | |
AR007856A1 (es) | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina, quinasa, sus metodos de prepraracion, intermediarios, uso en medicina ycomposiciones farmaceuticas que los contienen | |
CR20120009A (es) | 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728) | |
SV1998000029A (es) | Compuestos de pirazina ref. pg3186 | |
GT199800158AA (es) | Agonistas de prostaglandinas y su uso para tratar trastornos oseos | |
GT199900070A (es) | Derivados de isotiazol, utiles como agentes anticancerosos. | |
AR007961A1 (es) | Derivados de cicloalquilo como inhibidores de la resorcion osea y antagonistas de receptores de vitronectina, procedimiento para su preparacion y preparado farmaceutico. | |
AR005987A1 (es) | Terapia combinada para la osteoporosis | |
MX9302475A (es) | Polipeptido de origen no natural que tiene la actividad del factor recombinante de estimulacion del receptor neu y proceso para la produccion del mis mo. | |
AR018201A1 (es) | Compuesto de mesilato de n-(3-etinilfenil)-6,7-bis-(2-metoxietoxi)-4-quinazolinamina, composiciones que los contienen y su uso de dichos compuestos para la preparacion de medicamentos. | |
PA8457001A1 (es) | Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol | |
ES2161718T3 (es) | 2,5-dioxo-2,5-dihidro-1h-benzo(b)azepinas como antagonistas de los receptores de nmda. | |
ES2179352T3 (es) | Compuesto de pirazolopiridina y su uso farmaceutico. | |
ES2078455T3 (es) | 3-aril-4(3h)quinazolinonas antagonistas de cck y formulados farmaceuticos de las mismas. | |
MX9400070A (es) | Compuestos heterociclicos, un procedimiento para prepararlos, su uso y composiciones farmaceuticas que los contienen. |